Tags

Type your tag names separated by a space and hit enter

Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy.
Eur Ann Allergy Clin Immunol. 2011 Mar; 43(2):45-53.EA

Abstract

OBJECTIVE

Omalizumab (OM), an innovative biological treatment for difficult asthma with perennial sensitisations, is an humanized monoclonal anti-IgE antibody that binds free circulating IgE; inhibits mast cell and basophil activation by combining free IgE, leads to IgE receptor down-regulation, thus blocking the inflammatory cascade.

AIM OF THE STUDY

To assess real-world cost-utility ofadd-on OM in Italy.

METHODS

changes in clinical and economical outcomes, and in quality of life (QoL) associated with add-on OM in adults (n=23) with severe dfficult asthma were compared with those recorded before OM in the same subjects. Variables were: lung function; IgE levels; health status; ACT score; QoL (SGRQ); n. GP and specialist visits; emergency visits; hospitalizations, and concomitant pharmacological treatments. Further indices were: changes in Health-related QoL; total health-care costs, and incremental cost/utility. Data were statistically compared (Student's T test), and p < 0.01 was accepted for statistical significance.

RESULTS

asthma clinical outcomes and patients' health-related quality of life improved significantly by adding OM, and both costs for drugs and hospital care dropped significantly (p < 0.01). The net economic effect was a 350 Euro increase in overall monthly costs; when related to health benefits, it corresponded to an incremental cost/utility ratio ofabout 26,000 Euro/QALY, which represents a quite favourable figure in terms of willingness to pay for health benefits in industrialised countries.

CONCLUSIONS

Omalizumab added to an optimised therapy significantly improves clinical outcomes in difficult-to-treat, persistent allergic asthma. Costs also increased, but proved justified by health benefits achieved.

Authors+Show Affiliations

Lung Dept., Orlandi Gen. Hospital, Bussolengo, Verona, Italy. rdalnegro@ulss22.ven.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

21608372

Citation

Dal Negro, R W., et al. "Cost-utility of Add-on Omalizumab in Difficult-to-treat Allergic Asthma in Italy." European Annals of Allergy and Clinical Immunology, vol. 43, no. 2, 2011, pp. 45-53.
Dal Negro RW, Pradelli L, Tognella S, et al. Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy. Eur Ann Allergy Clin Immunol. 2011;43(2):45-53.
Dal Negro, R. W., Pradelli, L., Tognella, S., Micheletto, C., & Iannazzo, S. (2011). Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy. European Annals of Allergy and Clinical Immunology, 43(2), 45-53.
Dal Negro RW, et al. Cost-utility of Add-on Omalizumab in Difficult-to-treat Allergic Asthma in Italy. Eur Ann Allergy Clin Immunol. 2011;43(2):45-53. PubMed PMID: 21608372.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy. AU - Dal Negro,R W, AU - Pradelli,L, AU - Tognella,S, AU - Micheletto,C, AU - Iannazzo,S, PY - 2011/5/26/entrez PY - 2011/5/26/pubmed PY - 2011/6/10/medline SP - 45 EP - 53 JF - European annals of allergy and clinical immunology JO - Eur Ann Allergy Clin Immunol VL - 43 IS - 2 N2 - OBJECTIVE: Omalizumab (OM), an innovative biological treatment for difficult asthma with perennial sensitisations, is an humanized monoclonal anti-IgE antibody that binds free circulating IgE; inhibits mast cell and basophil activation by combining free IgE, leads to IgE receptor down-regulation, thus blocking the inflammatory cascade. AIM OF THE STUDY: To assess real-world cost-utility ofadd-on OM in Italy. METHODS: changes in clinical and economical outcomes, and in quality of life (QoL) associated with add-on OM in adults (n=23) with severe dfficult asthma were compared with those recorded before OM in the same subjects. Variables were: lung function; IgE levels; health status; ACT score; QoL (SGRQ); n. GP and specialist visits; emergency visits; hospitalizations, and concomitant pharmacological treatments. Further indices were: changes in Health-related QoL; total health-care costs, and incremental cost/utility. Data were statistically compared (Student's T test), and p < 0.01 was accepted for statistical significance. RESULTS: asthma clinical outcomes and patients' health-related quality of life improved significantly by adding OM, and both costs for drugs and hospital care dropped significantly (p < 0.01). The net economic effect was a 350 Euro increase in overall monthly costs; when related to health benefits, it corresponded to an incremental cost/utility ratio ofabout 26,000 Euro/QALY, which represents a quite favourable figure in terms of willingness to pay for health benefits in industrialised countries. CONCLUSIONS: Omalizumab added to an optimised therapy significantly improves clinical outcomes in difficult-to-treat, persistent allergic asthma. Costs also increased, but proved justified by health benefits achieved. SN - 1764-1489 UR - https://www.unboundmedicine.com/medline/citation/21608372/Cost_utility_of_add_on_omalizumab_in_difficult_to_treat_allergic_asthma_in_Italy_ L2 - http://www.diseaseinfosearch.org/result/633 DB - PRIME DP - Unbound Medicine ER -